Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue:        
Contract research revenue $ 89,812 $ 89,813 $ 89,812 $ 119,750
Costs and expenses:        
Research and development 2,828,776 1,522,695 5,143,477 3,715,584
General and administrative 1,781,717 1,972,048 3,570,131 3,929,847
Total costs and expenses 4,610,493 3,494,743 8,713,608 7,645,431
Loss from operations (4,520,681) (3,404,930) (8,623,796) (7,525,681)
Sale of New Jersey net operating loss 1,007,082 1,007,082
Other income/(expense), net 168,872 (6,101) 221,279 4,644
Net loss (3,344,727) (3,411,031) (7,395,435) (7,521,037)
Preferred stock series A accumulated dividends (146,786) (146,786) (293,572) (294,072)
Preferred stock series B accumulated dividends (115,750) (21,849) (234,000) (21,849)
Net loss attributable to common shareholders $ (3,607,263) $ (3,579,666) $ (7,923,007) $ (7,836,958)
Net loss available for common shareholders per share - basic and diluted $ (0.03) $ (0.04) $ (0.06) $ (0.08)
Weighted average common shares outstanding - basic and diluted 143,104,941 94,034,837 130,306,907 93,787,752